Skip to content

Clinical trials

Phase 4 trials in Russia

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 4 Country / region: Russia Clear all

380 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20026
20039
200411
20059
200618
200718
200814
200928
201016
201128
201222
201318
201417
201518
201620
201722
201814
201918
202014
202118
202213
202311
20243
20258
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed287
Unknown status38
Terminated22
Recruiting17
Active, not recruiting10
Withdrawn3
Not yet recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche26
Novartis Pharmaceuticals23
GlaxoSmithKline21
Pfizer19
Materia Medica Holding14
Boehringer Ingelheim12
Eli Lilly and Company12
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12
Sanofi11
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 230
Arthritis, Rheumatoid14
Pulmonary Disease, Chronic Obstructive14
Atrial Fibrillation12
Diabetes Mellitus12
Stroke11
Hypertension10
Asthma8
Coronary Artery Disease8
Influenza, Human7

Trials

Showing 51 to 75 of 380. Each trial links to its page on Pharma Observatory.

280 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.